HomeAI · summaries
Storia in 2 fonti
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a…
- ·
benzinga.com
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical C
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.